Inovio Pharmaceuticals has reported positive interim results from the initial two cohorts in Phase I clinical trial of its Covid-19 vaccine candidate, INO-4800.

With funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Phase I trial initially recruited 40 healthy adults aged 18 to 50 years at two sites in the US. Participants were given two 1mg or 2mg doses of INO-4800 four weeks apart.

An analysis by independent Data Safety Monitoring Board showed that the Inovio Covid-19 vaccine candidate was generally safe and well-tolerated in all participants across both cohorts through week 8.

The company added that all ten reported adverse events (AEs) were grade 1 in severity, without any serious adverse events (SAEs).

Immunology assays, including tests for humoral and cellular immune responses, are being performed for both INO-4800 dose cohorts following two doses at week 6.

So far, preliminary data on humoral and T cell immune responses has revealed that 94% of total participants experienced overall immunological response rates.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Apart from the positive interim Phase I results, the company announced that INO-4800 was able to protect mice in SARS-CoV-2 viral challenge studies, where the vaccine candidate prevented viral replication in the lungs of animals.

Furthermore, INO-4800 has been chosen to be part of a non-human primate (NHP) challenge study under the US Government’s Operation Warp Speed programme.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion of INO-4800 in Operation Warp Speed.

“We are also pleased that INO-4800 vaccination abrogated viral replication in the lungs of mice challenged with SARS-CoV-2.”

The company has expanded the Phase I trial to include older participants in additional cohorts. It also intends to launch a Phase II/III efficacy trial in the coming months.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now